Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 2
2005 1
2006 5
2008 1
2009 2
2011 3
2012 3
2013 1
2014 2
2015 4
2016 2
2017 3
2018 3
2019 3
2020 2
2021 1
2022 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
[New directions of immunocorrection in multiple sclerosis].
Boyko AN, Khachanova NV, Melnikov MV, Sivertseva SA, Evdoshenko EP, Spirin NN, Vasilyev AV, Rozenson OL. Boyko AN, et al. Among authors: khachanova nv. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(2):103-109. doi: 10.17116/jnevro2020120021103. Zh Nevrol Psikhiatr Im S S Korsakova. 2020. PMID: 32307419 Review. Russian.
Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.
Evdoshenko E, Laskova K, Shumilina M, Nekrashevich E, Andreeva M, Neofidov N, Kalinin I, Nikitchenko D, Rogozina A, Kupaeva A, Bulanov I, Bakirtzis C, Grigoriadis N, Khachanova N, Davydovskaya M, Makshakov G. Evdoshenko E, et al. Among authors: khachanova n. J Int Neuropsychol Soc. 2022 May;28(5):503-510. doi: 10.1017/S1355617721000722. Epub 2021 Jun 16. J Int Neuropsychol Soc. 2022. PMID: 34132190
[Clinical recommendations on the use of alemtuzumab (lemtrada)].
Alifirova VM, Bisaga GN, Boyko AN, Bryukhov VV, Davydovskay MV, Zakharova MN, Zakharova EV, Malkova NA, Popova EV, Salogub GN, Sivertseva SA, Troshina EA, Khachanova NV, Schmidt TE. Alifirova VM, et al. Among authors: khachanova nv. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):115-126. doi: 10.17116/jnevro201711722115-126. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28617370 Russian. No abstract available.
[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)].
Spirin NN, Vlasov YV, Zakharova MN, Khachanova NV, Popova EV, Khabirov FA, Totolyan NA, Sivertseva SA, Goncharova ZA, Korsunskaya LL, Yakushina TI, Matvievskaya OV, Simaniv TO, Boyko AN. Spirin NN, et al. Among authors: khachanova nv. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):84-88. doi: 10.17116/jnevro202212207284. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 35912562 Russian.
43 results